PMGC Holdings Inc 2026年季度报告

PMGC Holdings Inc. Quarterly Report on Form 10-Q PART I – FINANCIAL INFORMATION Item 1.Financial Statements1Notes to Unaudited Condensed Consolidated Financial Statements7 Forward-Looking Statements This Quarterly Report on Form 10-Q (this “Quarterly Report”) of PMGC Holdings Inc. (“we,” “us,” “our,” “PMGC” and the“Company”) contains statements that constitute “forward-looking statements” within the meaning of the safe harbor provisions of theU.S. Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical facts may be deemed to beforward-looking statements. These statements appear in several different places in this Quarterly Report and, in some cases, can beidentified by words such as “anticipates,” “estimates,” “projects,” “expects,” “contemplates,” “intends,” “believes,” “plans,” “may,”“will” or their negatives or other comparable words, although not all forward-looking statements contain these identifying words.Forward-looking statements in this Quarterly Report may include, but are not limited to, statements and/or information related to: our We have based these forward-looking statements on our current expectations about future events on information that is available as ofthe date of this Quarterly Report, and any forward-looking statements made by us speak only as of the date on which they are made.While we believe these expectations are reasonable, such forward-looking statements are inherently subject to risks and uncertainties,many of which are beyond our control. Our actual future results may differ materially from those discussed or implied in our forward-looking statements for various reasons, including, our ability to change the direction of the Company; our ability to keep pace with ●general economic and business conditions, including changes in interest rates;●prices of other competitive products, costs associated with research and development of our products and other economicconditions;●the effect of an outbreak of disease or similar public health threat, such as any future outbreak of COVID-19 on our business ●our ability to execute prospective business plans;●misjudgments in the course of preparing forward-looking statements;●our ability to raise sufficient funds to carry out our proposed business plan;●inability to keep up with advances in medical aesthetics and biotechnology; ●inability to design, develop, market and sell new medical aesthetics and biotech products that address additional marketopportunities to generate revenue and positive cash flows; ●dependency on certain key personnel and any inability to retain and attract qualified personnel;●our expectations regarding our ability to obtain, maintain, protect, defend and enforce our intellectual property rights andoperate without infringing, misappropriating, or otherwise violating the intellectual property rights of others; ●disruption of supply or shortage of raw materials; ●the unavailability, reduction or elimination of government and economic incentives; ●failure to manage future growth effectively; and ●the other risks and uncertainties detailed from time to time in our filings with the U.S. Securities and Exchange Commission(“SEC”), including, but not limited to, those described under “Risk Factors” in Part I, Item 1A of the Company’s AnnualReport on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025 (the “Form 10-K”). Although management has attempted to identify important factors that could cause actual results to differ materially from thosecontained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended.There is no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differmaterially from those anticipated in such forward-looking statements. Accordingly, readers should not place undue reliance on PART I - FINANCIAL INFORMATION Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)Condensed Consolidated Financial Statements of PMGC Holdings Inc. (formerly Elevai Labs Inc.)Condensed Consolidated Statements of Cash FlowsFor the three months ended March 31, 2026, and 2025 Supplemental cash flow information:Cash paid for interest Non-cash Investing and Financing transactions: PMGC Holdings Inc. (formerly Elevai Labs Inc.)Notes to the Condensed Consolidated Financial StatementsFor the three months ended March 31, 2026 and 2025 1.Organization and nature of operations PMGC Holdings Inc. (formerly Elevai Labs Inc.) (“PMGC”) was incorporated under the laws of the State of Delaware onJune 9, 2020. During 2024, PMGC completed a reorganization that included a name change and redomiciling from Delawareto Nevada. PMGC and its 100% owned subsidiaries, PMGC Research Inc. (formerly Elevai Research Inc) (“PMGCResearch”), PMGC Impasse Corp (formerly Elevai Skincare Inc.), Northstrive Biosciences Inc. (form